Digestive diseases and sciences · 2026
Outcomes and Characteristics Across Age Groups of Patients with Positive MT-sDNA Stool Tests: Data from the New Hampshire Colonoscopy Registry.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Anderson Joseph C, Hisey William M, Robinson Christina M, Limburg Paul J, Greene Mallik, Butterly Lynn F
Аннотация
BACKGROUND AND AIMS: Stool testing is a colorectal cancer (CRC) screening option for adults 45 years and older. Our aim was to examine characteristics and outcomes across age groups of patients who underwent colonoscopy following a positive multitarget stool DNA (mt-sDNA) test, compared to older age groups.
METHODS: We examined several outcomes reflecting both adenomatous and serrated pathways, including: any adenoma, clinically relevant serrated polyps (CRSPs, defined as sessile serrated polyps, traditional serrated adenomas, or hyperplastic polyps ≥ 1 cm) and advanced adenomas (AA, defined as any villous or tubulovillous adenomas, or tubular adenomas > 1 cm). Logistic regression models assessed the association between continuous age and each outcome, adjusting for patient sex and other relevant covariates.
RESULTS: The yield of advanced adenomas and CRSPs were equally high across all age groups, including the youngest group; we found no difference in the yield of AAs (OR = 0.99;95%CI:0.91-1.07) or CRSPs (OR = 0.95%CI:0.88-1.03) with increasing age. In contrast, the odds of any adenoma increased significantly with age (OR = 1.17;95%CI:1.09-1.26).
CONCLUSIONS: The yield of clinically significant polyps at colonoscopy following a positive multitarget stool DNA (mt-sDNA) test was similarly high across age groups. These findings suggest that mt-sDNA screening provides comparable clinical benefit across all ages of screening-eligible populations. The consistently high detection of advanced polyps across age groups likely reflects the strong positive predictive value of mt-sDNA testing.
METHODS: We examined several outcomes reflecting both adenomatous and serrated pathways, including: any adenoma, clinically relevant serrated polyps (CRSPs, defined as sessile serrated polyps, traditional serrated adenomas, or hyperplastic polyps ≥ 1 cm) and advanced adenomas (AA, defined as any villous or tubulovillous adenomas, or tubular adenomas > 1 cm). Logistic regression models assessed the association between continuous age and each outcome, adjusting for patient sex and other relevant covariates.
RESULTS: The yield of advanced adenomas and CRSPs were equally high across all age groups, including the youngest group; we found no difference in the yield of AAs (OR = 0.99;95%CI:0.91-1.07) or CRSPs (OR = 0.95%CI:0.88-1.03) with increasing age. In contrast, the odds of any adenoma increased significantly with age (OR = 1.17;95%CI:1.09-1.26).
CONCLUSIONS: The yield of clinically significant polyps at colonoscopy following a positive multitarget stool DNA (mt-sDNA) test was similarly high across age groups. These findings suggest that mt-sDNA screening provides comparable clinical benefit across all ages of screening-eligible populations. The consistently high detection of advanced polyps across age groups likely reflects the strong positive predictive value of mt-sDNA testing.